Important note: Information in this article was accurate in 2009. The state of the art may have changed since the publication date.
Integrated Regional Information Networks - September 4, 2009
Researchers led by the International AIDS Vaccine Institute (IAVI) said the two new antibodies revealed what might be an "Achilles heel" of the virus; they will now try to exploit this weakness.
"The findings ... [published in the Science Journal this week] are an exciting advance toward the goal of an effective AIDS vaccine because now we've got a new, potentially better target ... for vaccine design," said Wayne Koff, senior vice president of research and development at IAVI, in a statement. "And, having identified this one, we're set up to find more, which should further accelerate global efforts in AIDS vaccine development."
The two newly discovered antibodies are produced by a minority of HIV-infected individuals and are described as "broadly neutralizing" because they can neutralize a high percentage of the many types of HIV in circulation worldwide.
These antibodies are widely believed to offer the best hope for developing an AIDS vaccine that would teach the body to produce antibodies before exposure to the virus. Before this discovery, only four antibodies to HIV had been found that were widely agreed to be broadly neutralizing.
The discovery by scientists from IAVI, the Scripps Research Institute, and biotechnology companies Theraclone Sciences and Monogram Biosciences, gives vaccine research a much needed shot in the arm after a series of setbacks.
In the past two years at least two major vaccine trials have been unsuccessful, leading some to call for public funding of AIDS vaccine research to be ended or diverted to existing HIV treatment and prevention efforts.
"The story of the discovery of these two new antibodies demonstrates the challenges of AIDS vaccine research, but also the power of the collaboration that formed to produce this advance," said Seth Berkley, president of IAVI.
"By working in this manner, I am confident we will continue to move toward solving the AIDS vaccine challenge, one of the greatest scientific and public health challenges of our time."
090904
IR090905
Copyright © 2009 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980 – 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .